NUS

EX-99.1

2 ef20072663_ex99-1.htm

PRESS RELEASE DATED MAY 7, 2026

Exhibit 99.1

FOR IMMEDIATE RELEASE

Nu Skin Enterprises Reports First Quarter Results

PROVO, Utah — May 7, 2026 — Nu Skin Enterprises Inc. (NYSE: NUS) today announced first quarter revenue results within its guidance range.

Executive Summary

Q1 2026 vs. Prior-year Quarter

Revenue

$320.6 million; (12.0)%

•     +1.1% FX impact or $3.9 million

Earnings Per Share (EPS)

$0.04 or $0.14 excluding certain charges compared to $2.14 or $0.23 excluding one-time gain from Mavely sale and other charges

Customers

669,535; (14)%

Paid Affiliates

120,850; (8)%

Sales Leaders

26,915; (13)%

“We delivered first quarter revenue in line with our expectations and made further progress in our strategic priorities while operating in a volatile environment,” said Ryan Napierski, Nu Skin president and CEO. “As we move through 2026, we are focused on empowering our sales leaders to scale our intelligent wellness platform with our latest innovation, Prysm iO™, ahead of our full consumer rollout in the second half. We also continue to invest in laying the groundwork to expand our presence in emerging markets, including the formal launch of India anticipated in late 2026, while continuing to improve our operational discipline to return value to shareholders.

“We are encouraged by early signs of improving paid affiliates and new sales leader development in several markets as our leaders begin integrating Prysm iO into their businesses and continue to build upon our leading anti-aging Tru Face® brand. We are focused on partnering with our sales force on leveraging the proprietary nutritional health biomarker tracking from Prysm iO to expand the channel as we prepare to drive customer subscriptions for our wellness products. While these initiatives will take time to develop, we remain confident that they will increase sales leader engagement and expand our global reach over time to drive the next phase of growth for Nu Skin.”

Nu Skin Enterprises Reports First Quarter 2026 Financial Results

page 2

Q1 2026 Year-over-year Operating Results

Revenue

$320.6 million compared to $364.5 million

•     +1.1% FX impact or $3.9 million

Gross Margin

66.9% or 67.9% excluding certain charges compared to 67.8%

•     Nu Skin business was 76.9% compared to 76.7%

Selling Expenses

34.3% compared to 32.5%

•     Nu Skin business was 40.5% compared to 38.7%

G&A Expenses

30.7% or 29.9% excluding certain charges compared to 31.1% or 28.9% excluding certain charges

Impairment Expenses

$1.8 million impairment compared to $25.1 million impairment

Operating Margin

1.3% or 3.6% excluding certain charges compared to (2.7)% or 6.4% excluding impairment and other charges

Interest Expense

$4.3 million compared to $3.3 million

Other Income (Expense)

$2.8 million compared to $(28.4) million

•     Prior year reflects $28.1 million unrealized loss on investment

Income Tax Rate

29.4% compared to 20.1%

EPS

$0.04 or $0.14 excluding certain charges compared to $2.14 or $0.23 excluding one-time gain from Mavely sale and other charges

Stockholder Value

Dividend Payments

$2.9 million

Stock Repurchases

$5.0 million

•     $137.3 million remaining in authorization

Q2 and Full-year 2026 Outlook

Q2 2026 Revenue

$330 to $360 million; (15)% to (7)%

•     Approximately 0% FX impact

Q2 2026 EPS

$0.15 to $0.25

2026 Revenue

$1.35 to $1.50 billion;  (9)% to 1%

•    Approximately (1)% FX impact

2026 EPS

$0.70 to $1.10 or $0.80 to $1.20 excluding certain charges

“In addition to delivering on revenue and adjusted earnings, we returned $8 million to shareholders in the form of dividends and share repurchases,” said Chelsea Lantz, interim chief financial officer. “We were also able to refinance our debt, extending our liquidity as we invest in growth initiatives and navigate market volatility while executing on our strategy. We are maintaining our annual guidance for 2026 on an adjusted basis. For the second quarter, we project revenue between $330 million and $360 million, with earnings per share in the range of $0.15 to $0.25.”

Nu Skin Enterprises Reports First Quarter 2026 Financial Results

page 3

Conference Call

The Nu Skin Enterprises management team will host a conference call with the investment community today at 5 p.m. (ET). Those wishing to access the webcast, as well as the financial information presented during the call, can visit the Investor Relations page on the company’s website at ir.nuskin.com. A replay of the webcast will be available on the same page through May 21, 2026.

About Nu Skin Enterprises Inc.

Nu Skin Enterprises Inc. (NYSE: NUS) is an intelligent beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by more than 40 years of scientific research, the company’s products help people look, feel and live their best with our newly introduced Prysm iO intelligent wellnes

false000102156100010215612026-02-122026-02-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

February 12, 2026

Date of Report (Date of earliest event reported)

NU SKIN ENTERPRISES, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-12421

87-0565309

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification Number)

75 West Center Street

Provo, Utah 84601

(Address of principal executive offices and zip code)

(801) 345-1000

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Class A Common Stock, $.001 par value

NUS

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02

Results of Operations and Financial Condition.

On February 12, 2026, Nu Skin Enterprises, Inc. (the “Company”) issued a press release announcing its financial results for the three-month and annual periods ended December 31, 2025, and certain other information. A copy of the press release is attached as Exhibit 99.1 to this report.

The information furnished pursuant to this Item 2.02 and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

99.1

Nu Skin Enterprises’ press release dated February 12, 2026, regarding financial results for the three-month and annual periods ended December 31, 2025.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NU SKIN ENTERPRISES, INC.

(Registrant)

/s/ James D. Thomas

James D. Thomas

Chief Financial Officer

Date: February 12, 2026

false000102156100010215612025-11-062025-11-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

November 6, 2025

Date of Report (Date of earliest event reported)

NU SKIN ENTERPRISES, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-12421

87-0565309

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification Number)

75 West Center Street

Provo, Utah 84601

(Address of principal executive offices and zip code)

(801) 345-1000

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Class A Common Stock, $.001 par value

NUS

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02

Results of Operations and Financial Condition.

On November 6, 2025, Nu Skin Enterprises, Inc. (the “Company”) issued a press release announcing its financial results for the three- and nine-month periods ended September 30, 2025, and certain other information. A copy of the press release is attached as Exhibit 99.1 to this report.

The information furnished pursuant to this Item 2.02 and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

99.1

Nu Skin Enterprises’ press release dated November 6, 2025, regarding financial results for the three- and nine-month periods ended September 30, 2025.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NU SKIN ENTERPRISES, INC.

(Registrant)

/s/ James D. Thomas

James D. Thomas

Chief Financial Officer

Date:  November 6, 2025